Dupilumab hits marks in Phase III dermatitis trials

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and partner Sanofi (Euronext:SAN; NYSE:SNY) said dupilumab ( REGN668) met the primary endpoint in two identical Phase III trials to treat moderate to severe atopic dermatitis. Compared with placebo, dupilumab significantly

Read the full 354 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE